This is significant given therevived interest in treating high grade gliomas with poorly brainpermeable and highly cytotoxic drugs, as documented by the recentapproval of clinical studies where recurrent glioblastoma patientsare treated with albumin-bound PTXL upon permeabilization of the blood–brainbarrier via multiple, localized ultrasound sources.34 Despite all of this, the work has some limitations. This evidence concerns the gene ALB and central nervous system cancer.